Eli Lilly and Co (LLY) : Saturna Capital Corp scooped up 150 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 1,284,250 shares of Eli Lilly and Co which is valued at $103,459,180.Eli Lilly and Co makes up approximately 3.18% of Saturna Capital Corp’s portfolio.
Other Hedge Funds, Including , Hm Payson Co reduced its stake in LLY by selling 1,546 shares or 4.97% in the most recent quarter. The Hedge Fund company now holds 29,576 shares of LLY which is valued at $2,382,643. Eli Lilly and Co makes up approx 0.11% of Hm Payson Co’s portfolio.Strategy Asset Managers reduced its stake in LLY by selling 6,264 shares or 22.57% in the most recent quarter. The Hedge Fund company now holds 21,494 shares of LLY which is valued at $1,753,051. Eli Lilly and Co makes up approx 0.39% of Strategy Asset Managers’s portfolio.Wedbush Securities Inc boosted its stake in LLY in the latest quarter, The investment management firm added 1,451 additional shares and now holds a total of 15,342 shares of Eli Lilly and Co which is valued at $1,269,090. Eli Lilly and Co makes up approx 0.21% of Wedbush Securities Inc’s portfolio.Sanders Morris Harris reduced its stake in LLY by selling 1,193 shares or 11.61% in the most recent quarter. The Hedge Fund company now holds 9,084 shares of LLY which is valued at $757,606. Eli Lilly and Co makes up approx 0.19% of Sanders Morris Harris’s portfolio. Campbell Newman Asset Management Inc added LLY to its portfolio by purchasing 26,316 company shares during the most recent quarter which is valued at $2,088,438. Eli Lilly and Co makes up approx 0.37% of Campbell Newman Asset Management Inc’s portfolio.
Eli Lilly and Co opened for trading at $80.33 and hit $80.62 on the upside on Monday, eventually ending the session at $80.26, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 27,80,381 shares. Company has a market cap of $88,594 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.